What is Protonix used for?

Indications and Usage, quoted from the label by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. (NDA020988). Cross-references to other label sections are left out.

PROTONIX I.V. is indicated for treatment of:

• gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults and up to 7 days in pediatric patients 3 months and older.
• pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults.

Limitations of Use

The safety and effectiveness of PROTONIX I.V. for the treatment of upper gastrointestinal bleeding have not been established in adult or pediatric patients.

Source: DailyMed label, set id 51e4144a-489e-436c-609a-39305f8f56ba, version 60, effective December 22, 2025. NDC 0008-0923, one of 4 listings for this product.

Indications and Usage, quoted from the label by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. (NDA020987). Cross-references to other label sections are left out.

PROTONIX For Delayed-Release Oral Suspension and PROTONIX Delayed-Release Tablets are indicated for:

Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD)

PROTONIX is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (EE). For those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of PROTONIX may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established.

Maintenance of Healing of Erosive Esophagitis

PROTONIX is indicated for maintenance of healing of EE and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD. Controlled studies did not extend beyond 12 months.

Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome

PROTONIX is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison (ZE) Syndrome.

Source: DailyMed label, set id 08098cb2-c048-4640-f387-6beec4a38936, version 48, effective May 18, 2026. NDC 0008-0841, one of 2 listings for this product.